Insider Trading Alert - Illumina And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Sept. 6, 2013, 132 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $13.05 to $156,271,000.00.

Highlighted Stocks Traded by Insiders:

Illumina (ILMN) - FREE Research Report

Walt David R who is Director at Illumina sold 5,000 shares at $77.18 on Sept. 6, 2013. Following this transaction, the Director owned 931,488 shares meaning that the stake was reduced by 0.53% with the 5,000 share transaction.

The shares most recently traded at $79.73, up $2.55, or 3.2% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 25,062
  • 24-Week # shares sold: 55,383

The average volume for Illumina has been 1.0 million shares per day over the past 30 days. Illumina has a market cap of $9.9 billion and is part of the health care sector and drugs industry. Shares are up 42.96% year to date as of the close of trading on Friday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 92.4. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Molina Healthcare (MOH) - FREE Research Report

Romney Ronna who is Director at Molina Healthcare sold 2,000 shares at $35.12 on Sept. 6, 2013. Following this transaction, the Director owned 28,413 shares meaning that the stake was reduced by 6.58% with the 2,000 share transaction.

Murray Frank E MD who is Director at Molina Healthcare sold 5,000 shares at $34.70 on Sept. 6, 2013. Following this transaction, the Director owned 13,125 shares meaning that the stake was reduced by 27.59% with the 5,000 share transaction.

The shares most recently traded at $35.45, up $0.75, or 2.12% since the insider transaction. Historical insider transactions for Molina Healthcare go as follows:

  • 4-Week # shares sold: 132,517
  • 12-Week # shares sold: 269,400
  • 24-Week # shares sold: 292,839

The average volume for Molina Healthcare has been 504,800 shares per day over the past 30 days. Molina Healthcare has a market cap of $1.6 billion and is part of the health care sector and health services industry. Shares are up 30.08% year to date as of the close of trading on Friday.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals, as well as to assist state agencies in their administration of the Medicaid program. The company has a P/E ratio of 23.5. Currently there are 4 analysts that rate Molina Healthcare a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MOH - FREE

TheStreet Quant Ratings rates Molina Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Molina Healthcare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Qualcomm (QCOM) - FREE Research Report

Thompson James H who is Executive Vice President at Qualcomm sold 5,721 shares at $67.82 on Sept. 6, 2013. Following this transaction, the Executive Vice President owned 5,725 shares meaning that the stake was reduced by 49.98% with the 5,721 share transaction.

The shares most recently traded at $68.37, up $0.55, or 0.8% since the insider transaction. Historical insider transactions for Qualcomm go as follows:

  • 4-Week # shares sold: 5,164
  • 12-Week # shares sold: 6,418
  • 24-Week # shares sold: 50,727

The average volume for Qualcomm has been 12.7 million shares per day over the past 30 days. Qualcomm has a market cap of $116.4 billion and is part of the technology sector and telecommunications industry. Shares are up 9.65% year to date as of the close of trading on Friday.

QUALCOMM Incorporated designs, develops, manufactures, and markets digital telecommunications products and services. It operates in four segments: QCT, QTL, QWI, and QSI. The stock currently has a dividend yield of 2.06%. The company has a P/E ratio of 18.1. Currently there are 22 analysts that rate Qualcomm a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on QCOM - FREE

TheStreet Quant Ratings rates Qualcomm as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Qualcomm Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Teleflex (TFX) - FREE Research Report

Cook William Roland who is Director at Teleflex sold 2,696 shares at $77.32 on Sept. 6, 2013. Following this transaction, the Director owned 13,880 shares meaning that the stake was reduced by 16.26% with the 2,696 share transaction.

The shares most recently traded at $77.56, up $0.24, or 0.3% since the insider transaction. Historical insider transactions for Teleflex go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 4,000

The average volume for Teleflex has been 242,100 shares per day over the past 30 days. Teleflex has a market cap of $3.2 billion and is part of the health care sector and health services industry. Shares are up 8.82% year to date as of the close of trading on Friday.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures worldwide. The stock currently has a dividend yield of 1.76%. The company has a P/E ratio of 25.8. Currently there are 3 analysts that rate Teleflex a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TFX - FREE

TheStreet Quant Ratings rates Teleflex as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full Teleflex Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

URS Corporation (URS) - FREE Research Report

Wotring Randall A who is Pres. FS Div., Vice Pres at URS Corporation sold 21,861 shares at $50.33 on Sept. 6, 2013. Following this transaction, the Pres. FS Div., Vice Pres owned 111,854 shares meaning that the stake was reduced by 16.35% with the 21,861 share transaction.

The shares most recently traded at $50.73, up $0.40, or 0.79% since the insider transaction. Historical insider transactions for URS Corporation go as follows:

  • 4-Week # shares sold: 80,974
  • 12-Week # shares sold: 80,974
  • 24-Week # shares sold: 119,530

The average volume for URS Corporation has been 634,700 shares per day over the past 30 days. URS Corporation has a market cap of $3.8 billion and is part of the services sector and diversified services industry. Shares are up 26.85% year to date as of the close of trading on Friday.

URS Corporation provides engineering, construction, and technical services to public agencies and private sector clients worldwide. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 11.8. Currently there are 3 analysts that rate URS Corporation a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on URS - FREE

TheStreet Quant Ratings rates URS Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and attractive valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full URS Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing